Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Myxoid/round cell liposarcoma (MRCLS) is a type of liposarcoma (LS) mostly located in the limbs, with a variable behavior depending on the histological subtype. Both myxoid and round cell are distinct histological subtypes of LS.
Features include very common findings: Subcutaneous nodule; and sometimes findings: Abdominal pain and Gastrointestinal dysmotility.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 2 | Abdominal pain, Gastrointestinal dysmotility |
Phenotype severity distribution: 1 very common feature.
Estimated prevalence: Unknown (Unknown prevalence).
8 clinical trials registered, 6 recruiting. Interventions under study include drug therapy, procedural interventions, and biologic therapy. Pipeline includes 7 PHASE1, 1 EARLY_PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06083883](https://clinicaltrials.gov/study/NCT06083883) |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 5:23 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
1 |
Subcutaneous nodule |
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 |
PHASE1 |
M.D. Anderson Cancer Center |
RECRUITING |
[NCT06414434](https://clinicaltrials.gov/study/NCT06414434) | BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma | PHASE1 | Michael Wagner, MD | ACTIVE_NOT_RECRUITING |
[NCT07261657](https://clinicaltrials.gov/study/NCT07261657) | N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy | EARLY_PHASE1 | Seth Pollack | RECRUITING |
[NCT06843967](https://clinicaltrials.gov/study/NCT06843967) | A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma | PHASE1 | Memorial Sloan Kettering Cancer Center | RECRUITING |
[NCT05492682](https://clinicaltrials.gov/study/NCT05492682) | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | PHASE1 | Valo Therapeutics Oy | RECRUITING |
12 publications have been identified in PubMed for myxoid/round cell liposarcoma. Research spans Review / Meta-Analysis (50%), Case Report / Case Series (17%), and Clinical Trial Publication (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 6 | 50% |
Patient case studies | 2 | 17% |
Clinical study results | 2 | 17% |
Other research | 1 | 8% |
Laboratory research | 1 | 8% |
Dupont M (2026). [PMID: 41472526](https://pubmed.ncbi.nlm.nih.gov/41472526/). *Expert Rev Anticancer Ther*. [Review / Meta-Analysis]
Fradin JJ (2025). [PMID: 40282478](https://pubmed.ncbi.nlm.nih.gov/40282478/). *Cancers (Basel)*. [Review / Meta-Analysis]
Zou B (2025). [PMID: 40950305](https://pubmed.ncbi.nlm.nih.gov/40950305/). *Am J Transl Res*. [Basic Science / Preclinical]
Dupont M (2025). [PMID: 40423031](https://pubmed.ncbi.nlm.nih.gov/40423031/). *Curr Opin Oncol*. [Review / Meta-Analysis]
Knafler G (2025). [PMID: 39970827](https://pubmed.ncbi.nlm.nih.gov/39970827/). *Cancer Treat Rev*. [Review / Meta-Analysis]
Moussa T (2025). [PMID: 40378980](https://pubmed.ncbi.nlm.nih.gov/40378980/). *Magn Reson Imaging*. [Review / Meta-Analysis]
Hatipoglu E (2025). [PMID: 40245358](https://pubmed.ncbi.nlm.nih.gov/40245358/). *J Clin Oncol*. [Other]
D'Angelo SP (2025). [PMID: 39836945](https://pubmed.ncbi.nlm.nih.gov/39836945/). *J Clin Oncol*. [Clinical Trial Publication]
Kucharczyk M (2025). [PMID: 40810970](https://pubmed.ncbi.nlm.nih.gov/40810970/). *Curr Oncol Rep*. [Review / Meta-Analysis]
Shimatani A (2024). [PMID: 38656356](https://pubmed.ncbi.nlm.nih.gov/38656356/). *Int J Clin Oncol*. [Clinical Trial Publication]